CN1913902A - 使用喹硫平抗精神病药物治疗精神疾病 - Google Patents

使用喹硫平抗精神病药物治疗精神疾病 Download PDF

Info

Publication number
CN1913902A
CN1913902A CNA2005800036905A CN200580003690A CN1913902A CN 1913902 A CN1913902 A CN 1913902A CN A2005800036905 A CNA2005800036905 A CN A2005800036905A CN 200580003690 A CN200580003690 A CN 200580003690A CN 1913902 A CN1913902 A CN 1913902A
Authority
CN
China
Prior art keywords
quetiapine
treatment
bipolar disorder
patient
depressive symptom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800036905A
Other languages
English (en)
Chinese (zh)
Inventor
罗宾·麦科伊
布赖恩·奥尔特
吉尔伯特·布洛克
马丁·布雷彻
韦恩·麦克法登
玛格丽特·明克威茨
杰米·马伦
埃利斯·威尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1913902A publication Critical patent/CN1913902A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
CNA2005800036905A 2004-01-30 2005-01-27 使用喹硫平抗精神病药物治疗精神疾病 Pending CN1913902A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54061804P 2004-01-30 2004-01-30
US60/540,618 2004-01-30

Publications (1)

Publication Number Publication Date
CN1913902A true CN1913902A (zh) 2007-02-14

Family

ID=34826230

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800036905A Pending CN1913902A (zh) 2004-01-30 2005-01-27 使用喹硫平抗精神病药物治疗精神疾病

Country Status (13)

Country Link
US (2) US20050171088A1 (enExample)
EP (1) EP1713488A1 (enExample)
JP (1) JP2007520488A (enExample)
KR (1) KR20070011276A (enExample)
CN (1) CN1913902A (enExample)
AU (1) AU2005209142A1 (enExample)
BR (1) BRPI0507086A (enExample)
CA (1) CA2495361A1 (enExample)
IL (1) IL176999A0 (enExample)
NO (1) NO20063856L (enExample)
RU (1) RU2006130687A (enExample)
WO (1) WO2005072742A1 (enExample)
ZA (1) ZA200606128B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102631350A (zh) * 2012-03-29 2012-08-15 南京正科制药有限公司 一种富马酸喹硫平与鲁拉西酮的复方制剂
CN102716133A (zh) * 2012-04-06 2012-10-10 中国人民解放军第三军医大学 喹硫平在制备预防和治疗自身免疫性疾病的药物中的应用
CN109464451A (zh) * 2019-01-15 2019-03-15 范崇桂 一种治疗神经衰弱的药物及其制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
EP1838325A1 (en) * 2005-01-07 2007-10-03 AstraZeneca AB NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2021325A2 (en) 2006-05-09 2009-02-11 AstraZeneca AB Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
US8682445B2 (en) * 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
JP2010514684A (ja) * 2006-12-20 2010-05-06 アストラゼネカ・アクチエボラーグ 化合物及びその使用
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
RS58335B1 (sr) 2010-03-11 2019-03-29 Kempharm Inc Konjugati kvetiapina sa masnom kiselinom, proces za njihovo dobijanje i njihova primena
BR112012029326A2 (pt) 2010-05-20 2017-08-08 Astrazeneca Ab processo para a preparação de animais olefínicas substituídas por arila
RU2717939C1 (ru) * 2019-10-29 2020-03-27 Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе Способ лечения интоксикационных психозов при острых отравлениях психоактивными веществами

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US20030027817A1 (en) * 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6194466B1 (en) * 1998-10-15 2001-02-27 Elizabeth Marie Cottingham Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
US20030096808A1 (en) * 1999-03-29 2003-05-22 Jon M. Miller Substance to prevent or reverse weight gain induced by psychoactive agents
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US6350773B1 (en) * 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US20020061339A1 (en) * 2000-09-28 2002-05-23 Martin Stogniew Compositions and methods for use of extracts of rutaceae plants
US20050054942A1 (en) * 2002-01-22 2005-03-10 Melker Richard J. System and method for therapeutic drug monitoring
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
DE60219761T2 (de) * 2001-02-06 2008-01-17 Astrazeneca Ab Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
US20020123490A1 (en) * 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
JP2004527553A (ja) * 2001-04-26 2004-09-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗痙攣性誘導体と非典型的抗精神病薬を用いた共治療を含んで成る精神病性障害治療
US6621096B2 (en) * 2001-05-21 2003-09-16 Hewlett-Packard Develpoment Company, L.P. Device isolation process flow for ARS system
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US20040204469A1 (en) * 2001-06-19 2004-10-14 Norbert Muller Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
CN1547473A (zh) * 2001-07-23 2004-11-17 �Ƹ��� 预防由抗精神病药物引起的体重增加的方法
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
GB0202900D0 (en) * 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
US6831077B2 (en) * 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
CA2494109A1 (en) * 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
EP1551393A4 (en) * 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
WO2004064753A2 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US20050171139A1 (en) * 2003-10-07 2005-08-04 Hammer Ronald P.Jr. Treating psychotic symptoms
WO2005041935A1 (en) * 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
BRPI0417749A (pt) * 2003-12-22 2007-04-10 Acadia Pharm Inc composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
EP1699488A2 (en) * 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
BRPI0507250A (pt) * 2004-01-29 2007-06-26 Pfizer Prod Inc combinações para tratar desordens do snc
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
CA2556160A1 (en) * 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
US20050181071A1 (en) * 2004-02-18 2005-08-18 Binder Michael R. Method for the treatment of clinical depression
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
WO2005107808A2 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US8285900B2 (en) * 2009-02-17 2012-10-09 The Board Of Regents Of The University Of Texas System Method and apparatus for congestion-aware routing in a computer interconnection network

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102631350A (zh) * 2012-03-29 2012-08-15 南京正科制药有限公司 一种富马酸喹硫平与鲁拉西酮的复方制剂
CN102631350B (zh) * 2012-03-29 2013-10-16 南京正科制药有限公司 一种富马酸喹硫平与鲁拉西酮的复方制剂
CN102716133A (zh) * 2012-04-06 2012-10-10 中国人民解放军第三军医大学 喹硫平在制备预防和治疗自身免疫性疾病的药物中的应用
CN109464451A (zh) * 2019-01-15 2019-03-15 范崇桂 一种治疗神经衰弱的药物及其制备方法

Also Published As

Publication number Publication date
BRPI0507086A (pt) 2007-06-19
EP1713488A1 (en) 2006-10-25
KR20070011276A (ko) 2007-01-24
NO20063856L (no) 2006-10-26
IL176999A0 (en) 2006-12-10
CA2495361A1 (en) 2005-07-30
ZA200606128B (en) 2007-11-28
US20050171088A1 (en) 2005-08-04
US20100311718A1 (en) 2010-12-09
RU2006130687A (ru) 2008-03-10
AU2005209142A1 (en) 2005-08-11
WO2005072742A1 (en) 2005-08-11
JP2007520488A (ja) 2007-07-26

Similar Documents

Publication Publication Date Title
US20100311718A1 (en) Treatment of Psychoses with Dibenzothiazepine Antipsychotic
US10478442B2 (en) Method for the treatment of Dravet Syndrome
US6335021B1 (en) Composition for controlling mood disorders in healthy individuals
CN104853755B (zh) 包含沃替西汀和多奈哌齐的组合物
CN113710319B (zh) 用于治疗焦虑相关病症的组合物和方法
DK166479B (da) Anvendelse af fluoxetin, norfluoxetin eller et farmaceutisk acceptabelt salt af fluoxetin eller norfluoxetin til fremstilling af et laegemiddel med anxiolytisk virkning
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
CN1223349C (zh) 用于治疗抑郁症和相关病症的包括米氮平的联合用药物
JP2017508737A5 (enExample)
Askins Bailey et al. Atypical antipsychotics in late-life and treatment-resistant depression
EA201001640A1 (ru) Фармацевтическая антибактериальная композиция на основе наночастиц циклодекстрина, содержащих антибиотик из группы рифамицинов, способ ее получения и способы лечения
EP1359919A1 (en) Method of treating substance abuse with quetiapine
JP2008539265A5 (enExample)
RU2404976C1 (ru) Средство, снижающее влечение к алкоголизму, фармацевтическая композиция, способ ее получения, лекарственное средство и способ лечения
KR20230047509A (ko) 우울증의 예방 또는 치료용 벤조익산 또는 이의 염 및 유도체
US6977253B2 (en) Methods for the treatment of bipolar disorder using carbamazepine
MXPA06008131A (en) Treatment of psychoses with quetiapine antipsychotic
Grunze et al. Topiramate shows efficacy against mania in an open study with an on-off-on protocol
US20060094709A1 (en) Methods for the treatment of bipolar disorder using carbamazepine
Bowden et al. Risperidone treatment for acute mania: assessment of tolerability
CN103813791A (zh) 褪黑素的新用途
HK1256346B (en) Fenfluramine for use in the treatment of dravet syndrome
HK1256346A1 (en) Fenfluramine for use in the treatment of dravet syndrome
RU2018118645A (ru) Режим дозирования модулятора рецептора s1p
CN105943544A (zh) 一种治疗偏头痛的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication